Brought to you by 
Escient launches with $40mm Series A round
14 May 2018
Executive Summary
Escient Pharmaceuticals Inc. (GPCR-focused drug development) raised $40mm through a Series A round from a group of ten investors (according to the Form D filing) including The Column Group, 5AM Ventures, and Osage University Partners.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Escient launches with $40mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice